Compare ADMA Biologics Inc (ADMA) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Vanguard High Dividend Yield ETF — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Vanguard High Dividend Yield ETF trades at $160.13. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | VYM | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $161.17 |
52-Week Low | $7.60 | $132.90 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
VYM trades at $160.14, up 0.41% with a bullish technical outlook supported by moving averages. The ETF focuses on high dividend yield stocks, offering investors steady income through quarterly distributions. Recent news highlights strong investor interest in dividend ETFs for retirement income, with VYM being frequently compared to peers like VIG and SCHD for its diversification and low 0.04% expense ratio.
VYM presents a compelling income-focused investment with stable technical momentum, though RSI levels suggest potential near-term consolidation. The fund's broad diversification across 618 stocks provides resilience, but investors should monitor sector concentration risks and interest rate sensitivity that could impact dividend sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
